Publications by authors named "Masahiro Hatori"
Introduction: Cisplatin-based highly emetogenic chemotherapy is recommended in combination with neurokinin-1 receptor antagonist, 5-hydroxytryptamine-3-receptor antagonist (5HT3RA), dexamethasone (DEX), and olanzapine. However, olanzapine is contraindicated in patients with preexisting diabetes mellitus (DM). This study compared the efficacy of a triplet antiemetic regimen (NK1RA, 5HT3RA, and DEX) in patients with and without preexisting DM treated with cisplatin-based chemotherapy.
View Article and Find Full Text PDFBackground: Genetic polymorphisms of molecules are known to cause individual differences in the therapeutic efficacy of anticancer drugs. However, to date, germline mutations (but not somatic mutations) for anticancer drugs have not been adequately studied. The objective of this study was to investigate the association between germline polymorphisms of gemcitabine metabolic and transporter genes with carbohydrate antigen 19-9 (CA 19-9) response (decrease ≥50% from the pretreatment level at 8 weeks) and overall survival (OS) in patients with metastatic pancreatic cancer who receive gemcitabine-based chemotherapy.
View Article and Find Full Text PDFArticle Synopsis
- Dexamethasone is commonly used for preventing nausea and vomiting in chemotherapy patients but has notable side effects, leading to the exploration of a steroid-free antiemetic regimen.
- The study evaluated the effectiveness and safety of a combination of palonosetron, aprepitant, and olanzapine in patients receiving cisplatin, finding a total control rate of 31.3% and complete response rates of 61.4%, 84.3%, and 65.1% in different phases.
- While the primary endpoint wasn't met, the complete response rates were comparable to traditional regimens, suggesting this dexamethasone-free option could be beneficial for patients unable to use corticosteroids.
Article Synopsis
- * The study focused on leftover capecitabine tablets among gastric cancer patients receiving CAPOX chemotherapy, identifying nausea, missed doses, and diarrhea as primary causes for surplus.
- * Reusing leftover capecitabine at outpatient clinics not only helps in reducing overall medication costs—amounting to over JPY 600,000—but also highlights the importance of managing treatment adherence.
Background: Female sex and younger age are reported risk factors for chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy, but the underlying mechanism has not been elucidated. The purpose of this study was to clarify the impact of menopause on CINV.
Methods: This retrospective observational study analyzed data from consecutive patients who received their first cycle of perioperative anthracycline-based chemotherapy for breast cancer between January 2018 and June 2020.
The association between regorafenib dosage in the treatment of metastatic colorectal cancer (mCRC) and efficacy is currently not well established. It was previously reported that the regorafenib dose as prescribed is associated with efficacy, but doses in actual clinical settings have not been analyzed. We retrospectively analyzed patients with mCRC who had received regorafenib as third-line or later chemotherapy between May 2013 and June 2018.
View Article and Find Full Text PDFChemotherapy-induced neutropenia is one of the major adverse events which results in the reduction of chemotherapy. Doxorubicin is a substrate of the adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) transporter; reportedly, ABCB1 polymorphisms influence doxorubicin pharmacokinetics. We evaluated the association between chemotherapy-induced neutropenia and ABCB1 polymorphisms in patients with breast cancer.
View Article and Find Full Text PDFBackground: Neutropenia is one of the most important dose-limiting toxicities of docetaxel. Docetaxel is metabolized by cytochrome P450 3A4 (CYP3A4). Clarithromycin, a potent inhibitor of CYP3A4, is occasionally used in combination with docetaxel.
View Article and Find Full Text PDF